Last updated: August 31, 2026
Volixibat is an oral, locally acting ileal bile acid transporter inhibitor developed primarily by Shire and later owned by Takeda. It has been studied for cholestatic pruritus and cholestatic liver diseases, including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC). As of June 2024, volixibat had no FDA approval, no approved label, no Orange Book listing, and no publicly disclosed Phase 3 program or regulatory filing.
The commercial outlook is therefore highly conditional. If development resumes with a differentiated efficacy profile, volixibat could address a larger adult market than currently approved IBAT inhibitors, particularly in PBC and PSC. If Takeda has discontinued or deprioritized the program, the asset has greater value as an acquisition or partnering opportunity than as a near-term product launch.
What is volixibat and how does it work?
Volixibat, also known as SHP626, is an ileal bile acid transporter, or IBAT, inhibitor. IBAT is responsible for reabsorbing bile acids in the terminal ileum. Blocking the transporter increases fecal bile acid excretion and reduces enterohepatic bile acid circulation.
The intended therapeutic effects include:
- Lower circulating bile acid concentrations
- Reduction of bile acid accumulation in cholestatic disease
- Improvement in cholestatic pruritus
- Potential reduction of bile acid-mediated liver injury
Volixibat is designed to act primarily in the gastrointestinal tract, which may limit systemic exposure. Its main pharmacologic liability is diarrhea caused by increased bile acids reaching the colon. This class effect has also affected the development and commercial use of maralixibat and odevixibat.
Which diseases has volixibat targeted?
The principal development areas have included:
| Indication |
Development rationale |
Commercial status |
| Primary biliary cholangitis |
Treat cholestatic pruritus and reduce bile acid burden |
Investigational |
| Primary sclerosing cholangitis |
Address cholestasis and pruritus in a disease with limited approved therapies |
Investigational |
| Nonalcoholic steatohepatitis or related metabolic liver disease |
Explore bile acid modulation and liver-related endpoints |
No established commercial program |
| Other cholestatic disorders |
Potential expansion of IBAT mechanism |
No approved indication |
The strongest strategic rationale has been adult cholestatic disease rather than pediatric rare disease. Approved IBAT products have initially focused on pediatric disorders such as Alagille syndrome and progressive familial intrahepatic cholestasis.
What is the current development status of volixibat?
Volixibat remains an investigational drug. Public records through June 2024 do not show an FDA filing, marketing authorization, or commercial launch.
Takeda inherited volixibat through its 2019 acquisition of Shire. Takeda’s pipeline disclosures and public clinical-trial records do not establish a late-stage regulatory path for the asset. The absence of a Phase 3 program or regulatory submission materially reduces the probability of a launch in the near term.
What did clinical studies show?
Clinical studies evaluated volixibat in patients with cholestatic liver disease, with particular attention to pruritus, serum bile acids, liver biochemistry and tolerability.
The development profile has been mixed:
- Pharmacodynamic studies showed that volixibat can increase fecal bile acid loss and lower serum bile acid exposure.
- Some studies reported reductions in pruritus or improvements in pruritus-related measures.
- Diarrhea and gastrointestinal adverse events have been recurring tolerability issues.
- The relationship between biochemical effects and clinically meaningful improvement in liver outcomes remains unproven.
- No publicly established Phase 3 efficacy package supports approval.
For PBC, the key regulatory hurdle is demonstrating a durable and clinically meaningful benefit beyond existing treatments, including ursodeoxycholic acid, obeticholic acid where applicable, and emerging disease-modifying therapies. For PSC, the burden is higher because no drug has established a broad regulatory standard for disease modification.
When could volixibat reach the market?
There is no supportable near-term launch date based on the public development record.
A conventional development path would require:
- Confirmation of an active sponsor and target indication
- Completion of dose-ranging and pivotal Phase 2 work
- A Phase 3 program using accepted pruritus and liver-related endpoints
- FDA alignment on the approvable endpoint package
- NDA submission and review
- Resolution of patent, exclusivity and manufacturing issues
If a new sponsor restarted the program in 2025, a best-case U.S. launch would likely fall several years later. That scenario would require rapid regulatory alignment and a clear indication with a measurable benefit. A more probable commercial assumption is that volixibat remains inactive unless Takeda or a partner discloses a formal development restart.
What is the FDA regulatory status of volixibat?
Volixibat is not FDA-approved. It has no approved prescribing information, no FDA-recognized indication and no publicly identified NDA approval date.
The FDA regulatory position can be summarized as follows:
| Regulatory item |
Volixibat status |
| FDA approval |
None identified |
| Approved indication |
None |
| NDA or BLA approval |
None identified |
| Orange Book listing |
None |
| U.S. commercial launch |
None |
| Biosimilar pathway |
Not applicable |
| Generic approval pathway |
Not yet available because no approved reference product exists |
Volixibat is a small molecule, so the relevant post-approval competition would be an abbreviated new drug application, not a biosimilar application. A generic competitor could seek approval only after volixibat received an approved reference-product designation and applicable exclusivity and patent barriers were addressed.
What patents protect volixibat?
The public record does not provide a reliable basis for a complete, current list of volixibat patent numbers, claims and expiration dates. The asset’s likely patent protection would be distributed across several categories rather than a single compound patent.
What patent categories are likely relevant?
Potential protection may include:
- Composition-of-matter claims covering volixibat
- Salt, polymorph, crystalline-form or stereochemical claims
- Pharmaceutical-composition claims
- Oral dosage-form and release-profile claims
- Methods of treating cholestatic pruritus
- Methods of treating PBC or PSC
- Dosing regimens and patient-selection claims
- Manufacturing and impurity-control processes
The effective exclusivity position cannot be determined from the compound name alone. A complete analysis would require confirmation of the relevant patent families, national-stage filings, terminal disclaimers, patent-term adjustment, patent-term extension and any abandoned or expired applications.
Does volixibat have Orange Book patents?
No Orange Book listing is expected because volixibat has no FDA-approved product. Orange Book listings generally arise after NDA approval and are submitted by the holder of an approved drug application.
This means that:
- No publicly listed Orange Book patent blocks an ANDA today.
- No Paragraph IV challenge can target an approved volixibat reference product today.
- Any future patent challenge would depend on the patents listed after approval.
- Pre-approval patent disputes could still involve validity, infringement or ownership, but they would not be standard Orange Book ANDA litigation.
Are there Paragraph IV challenges or generic-entry risks?
No publicly established Paragraph IV litigation is associated with volixibat because there is no approved reference product and no known Orange Book listing.
The present generic-entry risk is therefore regulatory rather than litigation-based. If volixibat were approved, generic risk would depend on:
- Remaining term of the composition-of-matter patent
- Strength of method-of-use claims
- Whether formulation patents survive litigation
- Availability of non-infringing dosing regimens
- Market exclusivity granted for the approved indication
- The extent to which the product requires a proprietary formulation or manufacturing process
A broad, valid composition patent would offer the strongest protection. A portfolio consisting mainly of narrow method-of-use or formulation claims would create greater risk of early generic design-around.
How strong is the volixibat patent estate?
The patent estate cannot be rated as strong based solely on the publicly visible development record. Commercial strength is constrained by the absence of an approved product and the lack of a confirmed, consolidated patent map.
The estate would be commercially stronger if it includes:
- A surviving composition patent with meaningful term remaining
- Multiple independent claim sets covering salts, formulations and uses
- Patent-term adjustment or extension
- Claims aligned with the eventual FDA label
- Protection in the United States, Europe, Japan and other high-value markets
- Manufacturing claims that are difficult to design around
The estate would be weaker if:
- Core composition claims expire before launch
- The clinical indication falls outside the scope of issued method claims
- Diarrhea limits the usable dose or formulation
- Competing IBAT inhibitors offer similar efficacy
- The active ingredient can be manufactured through a readily available route
- The key patents are owned by different entities or subject to undisclosed encumbrances
What geographic coverage matters?
For a future launch, the highest-value patent jurisdictions would be:
- United States
- European Patent Convention states
- Japan
- China
- Canada
- Australia
PBC and PSC are concentrated in developed healthcare markets with established hepatology treatment infrastructure. Patent coverage in the United States and Europe would have the greatest impact on asset value. China and Japan could become important for long-term commercial expansion but would likely contribute less to initial peak sales than the United States and major European markets.
Which companies compete with volixibat?
Volixibat would compete in two markets: cholestatic pruritus and broader IBAT-mediated bile acid disorders.
| Product |
Company |
Mechanism |
Commercial position |
| Livmarli, maralixibat |
Mirum Pharmaceuticals |
IBAT inhibitor |
Approved for pediatric cholestatic disease |
| Bylvay, odevixibat |
Ipsen, formerly Albireo |
IBAT inhibitor |
Approved for pediatric cholestatic disorders |
| Urso products |
Multiple manufacturers |
Bile acid therapy |
Established treatment in PBC |
| Elafibranor |
Ipsen |
PPAR agonist |
Approved for PBC in Europe and later the U.S. |
| Seladelpar |
CymaBay, acquired by Gilead |
PPAR-delta agonist |
Late-stage PBC competitor before its 2024 FDA approval |
| Rifampicin, naltrexone, antihistamines |
Multiple manufacturers |
Symptom-directed therapy |
Used off-label for cholestatic pruritus |
Maralixibat and odevixibat validate the IBAT mechanism but also demonstrate the commercial importance of tolerability, dosing convenience and pediatric labeling. Their approved indications do not eliminate the possibility of an adult PBC or PSC opportunity for volixibat, but they establish physician familiarity and competitive benchmarks.
What formulations are protected by volixibat?
Volixibat has been developed as an oral drug. The key formulation issues are likely to include:
- Tablet or capsule stability
- Low systemic exposure
- Consistent intestinal delivery
- Dose flexibility
- Reduction of diarrhea and abdominal discomfort
- Compatibility with concomitant bile acid therapies
A formulation that improves gastrointestinal tolerability could create meaningful differentiation. Conversely, if diarrhea remains dose-limiting, a formulation patent may have limited commercial value even if technically valid.
Formulation protection is most valuable when it supports a commercially necessary product characteristic, such as once-daily dosing, improved exposure at the site of action or reduced adverse events.
What is the licensing and ownership history of volixibat?
Volixibat was associated with Shire and subsequently transferred to Takeda through Takeda’s acquisition of Shire in 2019. No major separate licensing agreement specifically involving volixibat has been publicly established in the cited materials.
Ownership and partnering risk should be reviewed carefully because:
- The original patent applicant may differ from the current commercial owner.
- Clinical development rights may be subject to regional arrangements.
- Patent assignments may not track development announcements.
- An inactive program may be available for out-licensing without a public transaction.
- Any transaction would require review of patent prosecution, clinical data rights and manufacturing know-how.
What market could volixibat address?
The most credible commercial opportunity is adult cholestatic pruritus, especially in PBC and PSC.
PBC has a substantially larger diagnosed treatment population than rare pediatric cholestatic diseases. PSC has fewer patients but a high unmet-need profile and limited approved pharmacologic treatment. Volixibat could be commercially relevant if it demonstrates:
- Robust pruritus reduction
- A tolerable gastrointestinal profile
- Benefit in patients inadequately controlled by standard therapy
- A clear dosing advantage
- A label that includes a broad adult population
What is the projected peak-sales range?
A scenario-based projection is more appropriate than a point estimate.
| Scenario |
Development assumption |
Potential peak revenue |
| Low |
No restart or narrow label after limited efficacy |
$0-$50 million |
| Base |
Approval for a defined PBC population with moderate uptake |
$100-$300 million |
| Upside |
Approval in PBC and PSC with differentiated pruritus control |
$300-$700 million |
| High |
Broad adult cholestatic indication and strong global adoption |
Above $700 million |
These figures are gross commercial estimates, not forecasts of reported company revenue. The base case assumes an adult rare-disease pricing model, specialist prescribing and substantial competition. The upside case requires a label broader than a narrow rescue indication and clinical data that distinguish volixibat from existing IBAT inhibitors and off-label pruritus therapies.
What factors determine market penetration?
The principal commercial drivers are:
- Magnitude and durability of pruritus relief
- Diarrhea discontinuation rate
- Effect on liver biochemistry and disease progression
- Use alongside ursodeoxycholic acid or other PBC therapies
- Reimbursement for a chronic adult indication
- Label breadth
- Patent life at launch
- Physician confidence in long-term safety
- Availability of competing PBC products
A drug that improves symptoms without affecting disease progression could still generate meaningful revenue, but payer restrictions may be stronger. A product with both antipruritic and disease-modifying evidence would have a materially higher valuation.
What generic launch scenarios exist for volixibat?
If approved with long-lived composition protection, generic entry would probably be delayed until patent expiry or settlement. If composition protection is weak or expired, generic entry could occur after regulatory exclusivity ends, subject to formulation and method-of-use patents.
The main scenarios are:
Protected launch
A valid composition patent remains in force through the first commercial years. Generic entry risk is low, although authorized-generic or settlement arrangements could alter the timing.
Method-of-use dependence
The composition patent has limited remaining term and the product relies on indication-specific patents. Generic applicants could seek labels that omit protected uses, creating litigation and pharmacy-substitution issues.
Narrow formulation protection
The active ingredient is broadly available, but the commercial product relies on a formulation patent. Competitors could attempt alternative dosage forms or release profiles.
No meaningful launch protection
The program is approved after core patents expire or is commercialized with inadequate patent coverage. Price erosion could occur quickly after generic approval.
What patent litigation affects volixibat?
No publicly established Orange Book litigation or Paragraph IV case affects volixibat as of June 2024. The absence of litigation reflects the asset’s pre-approval status rather than a finding that its patent estate is unchallenged or commercially secure.
Future disputes could involve:
- Validity of composition claims
- Obviousness of IBAT inhibitor structures
- Infringement by generic dosing regimens
- Ownership of Shire-originated patents
- Patent-term calculations
- Formulation and manufacturing claims
- Antitrust issues arising from settlements
Key Takeaways
- Volixibat is an investigational oral IBAT inhibitor, also known as SHP626.
- Its principal targets have been PBC, PSC and related cholestatic conditions.
- No FDA approval, NDA approval, Orange Book listing or commercial launch has been established through June 2024.
- Public evidence does not support a near-term launch date or confirmed Phase 3 path.
- The key clinical tradeoff is bile acid reduction and possible antipruritic activity versus gastrointestinal tolerability.
- No Paragraph IV challenge or generic litigation is publicly established.
- Takeda acquired the asset through its acquisition of Shire.
- A realistic conditional peak-sales range is approximately $100 million to $300 million, with upside toward $700 million if volixibat gains a differentiated PBC and PSC label.
- The commercial value of the program depends heavily on whether composition-of-matter and indication-specific patent rights remain enforceable at launch.
FAQs
Is volixibat approved for primary biliary cholangitis?
No. Volixibat is not FDA-approved for PBC and has no approved commercial label.
Is volixibat the same as maralixibat or odevixibat?
No. All three are IBAT inhibitors, but volixibat, maralixibat and odevixibat are distinct active ingredients developed by different companies.
Can volixibat treat primary sclerosing cholangitis?
Volixibat has been investigated for PSC, but clinical investigation does not establish an approved indication or proven disease-modifying benefit.
Does volixibat have biosimilar competition?
No. Volixibat is a small molecule, so any future copy product would follow the generic drug pathway rather than the biosimilar pathway.
Could volixibat be licensed to another pharmaceutical company?
Yes. Its acquisition history and lack of a disclosed commercial launch leave open the possibility of out-licensing or asset sale, but no major volixibat-specific licensing transaction is publicly established in the cited sources.
References
-
ClinicalTrials.gov. (n.d.). Search results for volixibat and SHP626 clinical studies. U.S. National Library of Medicine. https://clinicaltrials.gov/search?term=volixibat
-
Takeda Pharmaceutical Company Limited. (2019). Takeda completes acquisition of Shire. https://www.takeda.com/newsroom/newsreleases/2019/takeda-completes-acquisition-of-shire/
-
U.S. Food and Drug Administration. (2021). FDA approves first treatment for Alagille syndrome. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-alagille-syndrome
-
U.S. Food and Drug Administration. (2021). FDA approves drug to treat rare liver disease. https://www.fda.gov/news-events/press-announcements/fda-approves-drug-treat-rare-liver-disease
-
U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
-
European Medicines Agency. (n.d.). Bylvay: EPAR. https://www.ema.europa.eu/en/medicines/human/EPAR/bylvay
-
European Medicines Agency. (n.d.). Livmarli: EPAR. https://www.ema.europa.eu/en/medicines/human/EPAR/livmarli
